|
This is a medication treatment study for adults with Body Dysmorphic Disorder in collaboration with Butler Hospital that seeks to establish the efficacy of Escitalopram, also known as Lexapro, in the treatment of this disorder. Additionally, this study seeks to determine whether individuals who do well on Escitalopram will continue to do well after discontinuation of the medication. It is hoped that some of the gains made during medication treatment can be maintained after the treatment has ceased. Lexapro is among the most highly recommended medications for BDD, although there is currently no FDA approved medication for BDD. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This study is designed to gather
information about mental health symptom profile, treatment
barriers, and treatment utilization among individuals
suffering from Body Dysmorphic Disorder by Proxy (BDD-BP).
By examining the etiology, symptomatic profile, and
prevalence of this disorder, this study will collect
preliminary data that can be used to help further future
research to develop better treatment options for individuals
with BDD by proxy.
To participate, please use this link:
https://www.surveymonkey.com/s/BDDBYPROXY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The purpose of this study is to develop and test the effectiveness of Cognitive-Behavioral Therapy (CBT) for children and adolescents suffering from Body Dysmorphic Disorder. CBT is the most effective psychological treatment for adults with BDD. Information we have so far suggests that CBT might prove effective in treating children and adolescents with BDD as well.
|
|
| |
| |
|
|
|
|
|
|
|
|
|
|
| |
This cross-sectional study seeks to investigate neuropsychological, psychosocial, cognitive, temperamental, and clinical factors that may contribute to the development and/or maintenance of obsessive-compulsive disorder (OCD) and body dysmorphic disorder (BDD), with an eye toward the development of prevention and early intervention strategies for OCD and BDD. Comprehensive assessments, including diagnostic interviews, neuropsychological tests, and self-report measures will be administered to children diagnosed with OCD or BDD or no disorder, and their first-degree relatives.
|
|
| |
| |
|
|
|
|
|
|
|
|
|
|
|
In this research study we seek to investigate the
effectiveness of D-cycloserine as a memory booster for Exposure and
Response Prevention in the treatment of Body Dysmorphic Disorder.
D-cycloserine is an antibiotic that has been used in the treatment of
tuberculosis for over 20 years. Research so far demonstrates
D-cycloserine does increase the effectiveness of Exposure and Response
Prevention in the treatment of Obsessive Compulsive Disorder. We would
like to expand this research with D-cycloserine to see if it is effective
with body dysmorphic disorder. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|